CETP inhibition with Anacetrapib Decreases Fractional Clearance Rates of HDL Apolipoprotein A-I and Plasma CETP

OBJECTIVE: Anacetrapib, an inhibitor of cholesteryl ester transfer protein (CETP) activity, increases plasma concentrations of HDL-C, apoA-I, apoA-II, and CETP. The mechanisms responsible for these treatment-related increases in apolipoproteins and plasma CETP are unknown. We performed a randomized,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Arterioscler Thromb Vasc Biol
Autores principales: Reyes-Soffer, Gissette, Millar, John S., Ngai, Colleen, Jumes, Patricia, Coromilas, Ellie, Asztalos, Bela, Johnson-Levonas, Amy O., Wagner, John A., Donovan, Daniel S., Karmally, Wahida, Ramakrishnan, Rajasekhar, Holleran, Stephen, Thomas, Tiffany, Dunbar, Richard L., deGoma, Emil M., Rafeek, Hashmi, Baer, Amanda L., Liu, Yang, Lassman, Michael E., Gutstein, David E., Rader, Daniel J., Ginsberg, Henry N.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4911016/
https://ncbi.nlm.nih.gov/pubmed/26966279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.115.306680
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares